Scene 1 (0s)
[image] A red text on a black background AI generated content may be incorrect.
Scene 2 (15s)
High Prevalence, low minimally-invasive treatments.
Scene 3 (54s)
From Blocked to Bypass. When doctors can't see or cross bypass surgery fills the gap.
Scene 4 (1m 22s)
Tigerheart™: See + Steer + Cross in one coronary crossing system to stay intraluminal.
Scene 5 (1m 48s)
It works: Only Tigerheart crossed a mature CTO in record time, is safe, biocompatible and stayed intraluminal1.
Scene 6 (2m 7s)
Robust IP stack: Owns 61 patents; Platform reusable across indications.
Scene 7 (2m 20s)
AI- Powered Precision. Vessel Sizing. Analyzes vessel layer images to suggest → Stent and Balloon Dimensions, minimizing wrong sizing.
Scene 8 (2m 38s)
Roadmap to Impact: Immediate & Future Priorities.
Scene 9 (3m 5s)
We've done this before: 2 decades of image-guided, FDA-cleared devices with global supply chain & customer footprint.
Scene 10 (3m 22s)
Tigerheart already signed licensing & royalty deals with largest players in China and India, active discussions with large MedTechs for ROW.
Scene 11 (3m 42s)
Adoption & Economics: Better for Payers, Providers & Patients.
Scene 12 (4m 2s)
Competition: Tigerheart is the only solution with see + steer + cross.
Scene 13 (4m 25s)
A close-up of a silver object Description automatically generated INTERCHANGEABLE DRIVE SHAFT Locks with spinning outer tip and is exchangeable with guidewire DEFLECTABLE TIP User controlled deflectable tip to steer device based on onboard imaging.
Scene 14 (4m 52s)
DEVELOPED IN COLABARATION WITH INDUSTRY EXPERTS LIVE PORCINE STUDIES AT BRIGHAM AND WOMEN’S HOSPITAL – WITH DR. KEVIN CROCE.
Scene 15 (5m 23s)
DEVELOPED IN COLABARATION WITH INDUSTRY EXPERTS. [image].
Scene 16 (6m 1s)
Hear From the Experts. Dr. Rajneesh | Cardiologist in Gurgaon | Medanta – The Medicity.
Scene 17 (6m 48s)
Clear path to FDA approval & commercialization: An animal study + 110 patient pivotal study.
Scene 18 (7m 17s)
Team has built image‑guided platforms for 35+ years and sold two other platforms to industry giants ($1Bn+), backed by a serial-entrepreneur.
Scene 19 (7m 50s)
Seed ask: $15M for regulatory approval (FDA + CDSCO) & commercialization.
Scene 20 (8m 6s)
Financial Overview. Metric (in USD M) Y1 Y2 Y3 Y4 Y5 Y6 Y7 Total Revenue $- $- $4.2 $15.8 $32.1 $56.3 $78.8 Gross Margin $- $- $2.9 $11.0 $22.5 $39.7 $55.7 EBIT $(2.8) $(2.5) $0.2 $7.0 $18.5 $34.9 $50.7 Free Cash Flow $(2.9) $(3.0) $(0.8) $5.5 $17.0 $33.4 $49.2 Funding Inflow $3.0 $3.0 $1.0 $- $- $- $- Cumulative Cash $0.1 $0.1 $0.3 $5.8 $22.8 $56.2 $105.3.
Scene 21 (9m 0s)
[image]. Thank you. Ajoy Khandheria – President [email protected] 415-359-7998 Himanshu Patel - CEO [email protected] 408-393-9568.
Scene 22 (9m 10s)
Appendix.
Scene 23 (9m 16s)
A high-impact team of visionaries and innovators.
Scene 24 (10m 35s)
Competition: Tigerheart is the only solution with see + steer + cross.
Scene 25 (10m 53s)
Market Map. [image]. Patients: All age group patients including seniors (age 60+), high-risk individuals, patients unfit for bypass surgery. Hospitals & Cath Labs: Centres performing angioplasty with CTO cases. Physicians: Interventional cardiologists seeking safer, predictable tools. Payers / Insurance: Existing CPT codes (USA), significant cost savings vs. bypass surgery (>$38,000). Regulatory Agencies: FDA IDE process underway; India CDSCO path in progress. Medical Tourism: large demand for safer and affordable CTO crossing procedures.